Close Menu
Home › Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Apr 15, 2019

This article has been updated with a statement from the Clinical Pharmacogenetics Implementation Consortium.

NEW YORK (GenomeWeb) – Inova Health System has decided to completely stop performing its suite of pharmacogenetic tests in response to a US Food and Drug Administration warning letter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

What's Popular?

In Regulatory News

  1. Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

  2. Beckman Coulter Early Sepsis Indicator Granted FDA Clearance

  3. FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer

  4. GenMark Diagnostics Obtains FDA Clearance for Gram-Negative Sepsis Panel

  5. Hologic Receives CE Mark for Cytology Slide, Molecular Sample Preparation Instrument

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.